Abstract:Endothelial monocyte-activating polypeptide-Ⅱ (EMAP-Ⅱ) is a novel proinflammatory cytokine with proinflammatory, proapoptotic and antiangiogenic properties. It is associated with many tumor-associated proteins, such as tumor necrosis factor, vascular endothelial growth factor, hypoxia inducible factor-1α, arginyl-tRNA synthetase, and insulin-like growth factor-Ⅰ. EMAP-Ⅱ has anti-tumor properties and has a good prospect in cancer prevention and treatment.